Despite a paucity of clinical trial proof, methotrexate is often advocated or mandated to treat psoriatic arthritis. A recent comparison of clinical trials outcomes fails to show any added value when MTX is given to PsA patients taking etanercept.

Obesity is epidemic in North America, affecting nearly 76 million adults. Obesity is not only a risk factor for rheumatoid arthritis and osteoarthritis, it clearly worsens pain and function in most musculoskeletal (MSK) conditions and has been shown to blunt DMARD and biologic resp

Silverman and a panel from the IOF Fracture Working Group reviewed the data and trials to develop guidelines for the use of osteoporosis medications after incident fractures or to treat delayed fracture healing.

Doshi and colleagues have conducted a retrospective claims analysis (2009 through 2012) of psoriasis patients on Medicare to examine the use and adherence to those initiating treatment with either infliximab, etanercept, adalimumab, or ustekinumab.

Like other extraarticular manifestations, rheumatoid (RA) or connective tissue disease (CTD) related interstitial lung disease (ILD) is difficult to identify early and equally challenging to treat.

It is important to know where you’ve been, as it will most certainly color where you are going. Hence, in honor of our 1st year anniversary, we have taken note of our most popular articles.

Watch Dr. Jack Cush cover ten highlights from this week on RheumNow.com.

Numerous guidelines (ACR, ACIP/CDC, ATS, NICE) all call for timely vaccinations in patients with rheumatoid arthritis (RA) and those receiving immunosuppressives or biologics. 

Amidst a stringent regulatory environment, and with the rising use and abuse of narcotics and increasing regulation limiting narcotic analgesic use, the FDA approved (August 2015) the use of extended-release oxycodone in children (11 to 16 years old) with severe, "around-the-clock" pain

Markusse and investigators from The Netherlands have reported their 10 year results of treating early rheumatoid arthritis (RA) patients using targeted treatment strategies.

Choi and colleagues analyzed US hospitalizations (2009–2013) to assess the frequency and racial distribution of patients hospitalized with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) related to the use of urate-lowering (ULT) therapy (predominantly allopurinol).

Video recap of highlights from this week at RheumNow.com.

Major advances in biosimilars have occurred in the last three months, beginning with the FDA Arthritis Advisory Committee voting 21-3 to approve Celltrion’s Inflectra (CT-P13) and ending with the recent approval of Inflectra (generically referred to as infliximab dyyb).

Systemic lupus is a clinically heterogeneous disorder, unified by requisite clinical features and exuberant humoral response to unknown triggers.  While the diagnosis is easy, the disease course and management can be complicated and challenging.  

In a retrospective cohort comparison study, 42,180 rheumatoid arthritis (RA) patients were compared 1:4 with 168,000 normal controls to examine the incidence of new tuberculosis in Taiwan. The RA population included those receiving csDMARDs (36,162), etanercept (3,577), adalimumab (1,67

Methotrexate (MTX) is a highly favored drug in rheumatology.  Yet it has numerous nuisance side effects that may limit its use or patient acceptance.

In March 2016, RheumNow published 82 social media “tweets” regarding news, research and teaching points that impact the rheumatology community. These feeds had a reach (impressions) of 86,400 with, 76 mentions, and over 2700 visits to learn on RheumNow.com.

Dr. Jack Cush reviews the rheumatology highlights from the news, media, and journals from this past week:

Lopez and colleagues from Spain have studied the gut microbiome of l

The GAUSS-3 trial, recently published in JAMA, examined cholesterol-lowering interventions in patients with a high LDL (>120 mg/dl) and a history of statin intolerance to 2 or more statins.